|
| Tuesday, 6 June 2023, 20:00 HKT/SGT | |
| |  | |
Source: GeneTex | |
|
|
|
IRVINE, CA, June 6, 2023 - (ACN Newswire) - GeneTex, a multinational antibody manufacturing company, is leveraging its recombinant monoclonal antibody production platform to produce best-in-class biomedical research reagents. The specificity of these new antibodies is established through meticulous in-house validation testing based on knockdown/knockout methodologies complemented by other strategies. GeneTex has employed this process to develop and thoroughly validate its new programmed death-ligand 1 (PD-L1) recombinant rabbit monoclonal antibody for immunohistochemistry (IHC).
The interaction between PD-L1 (CD274/B7-H1) and its receptor programmed death-1 (PD-1) is not only a focus of cancer immunotherapy research but also has major therapeutic relevance for many solid malignancies. PD-L1 is an immune checkpoint inhibitor that binds to PD-1 expressed on T cells and other effectors to quash immune system overactivation and autoimmunity. Cancer cells exploit this and overexpress PD-L1, creating an immunosuppressive state through induced cell death of anti-tumor T cells. Thus, gauging PD-L1 expression on tumor cells can identify cancers that may respond to anti-PD-L1/PD-1 agents. Given the importance of PD-L1 detection in patient tumor samples for both prognostic and treatment considerations, reliable reagents are clearly essential for both research and clinical decision-making.
Immunohistochemistry is utilized routinely in both academic and clinical settings to determine PD-L1 expression in both normal and cancerous tissues. GeneTex's recombinant rabbit monoclonal antibody (PD-L1 antibody [HL1041]) is a cited, PD-L1-specific, knockout-validated reagent that performs in three applications (i.e., western blot, immunocytochemistry, and IHC). To further evaluate this antibody's IHC capabilities, GeneTex enlisted the assistance of MS Validated Antibodies GmbH (MSVA), a company with demonstrated proficiency in IHC optimization that has assessed over 5000 antibodies for their functionality in formalin-fixed tissue IHC. MSVA completed an extensive analysis of the GeneTex antibody's staining on tumor samples and a broad array of normal tissues, comparing the signal to that of another well-established PD-L1 antibody (see Figure). GeneTex clone [HL1041] exhibited excellent sensitivity and specificity. Marco Sauter, MSVA CEO, commented, "As formalin fixation alters the structure and accessibility of many epitopes, a trustworthy antibody validation for IHC invariably requires the analysis of a very broad range of formalin-fixed tissues. Our analysis of more than 70 different normal tissue types and of a broad range of different cancers exceeds what regulatory agencies currently require. We are gratified that our MSVA approach could help to identify PD-L1 clone [HL1041] with binding properties that are comparable to the most established PD-L1 antibodies on the market."
The need for quality antibodies to visualize the expression of biomarkers crucial for cancer biology research and patient care remains vast, particularly for IHC. GeneTex is presently developing reagents against a number of key targets. Allen Lee, GeneTex's Vice President of Business Development, stressed the importance of expertise-based collaborations to create gold-standard products for scientists and clinicians: "GeneTex is excited to extend our partnership with MSVA. Their IHC validation services align perfectly with GeneTex's core mission, which is to provide the biomedical community with the highest quality immunological reagents supported by extensive research, development, and validation."
GeneTex products are for research use only. Not for diagnostic or therapeutic procedures.
Media Contact:
Allen Lee
Phone: 949.553.1900
Email: allensl@genetex.com
www.genetex.com
Contact Information
Allen Lee
Vice President - Business Development
allensl@genetex.com
(949)553-1900
Topic: Press release summary
Source: GeneTex
Sectors: BioTech, Healthcare & Pharm
https://www.acnnewswire.com
From the Asia Corporate News Network
Copyright © 2026 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
|
|
|
|
|
|
|
| |
Latest Press Releases
Mr Liu Xiaojun, on behalf of Fufeng Group, has fully completed the acquisition of Viva World Trade, Inc.
Feb 7, 2026 05:45 HKT/SGT
|
|
|
GIC Invests US$100M in Ascletis Pharma (1672. HK): Anchoring Long-Term Capital in China's Core Innovative Drug Assets
Feb 6, 2026 17:45 HKT/SGT
|
|
|
GIC Private Limited initiated a stake in Ascletis Pharma (01672) by 64,128,000 shares at a price of HKD 12.18 per share
Feb 6, 2026 17:01 HKT/SGT
|
|
|
COSMOPlat Introduces Full-Stack AI to Hong Kong for Trillion-Dollar Industrial Digitalization
Feb 6, 2026 16:34 HKT/SGT
|
|
|
Everest Medicines Announces China NMPA Approval of VELSIPITY(R) for Adults with Moderately to Severely Active Ulcerative Colitis
Feb 6, 2026 14:17 HKT/SGT
|
|
|
Spritzer Celebrates Continued Excellence with Dual Recognition at Putra Brand Awards 2025 and Superior Taste Award 2025
Feb 6, 2026 13:13 HKT/SGT
|
|
|
Mitsubishi Motors Launches the All-New Versa Van in the Philippine Market
Friday, February 6, 2026 12:34:00 PM
|
|
|
Eternal Beauty Holdings Limited and Lane Crawford Debut Landmark Fragrance, Further Expanding Footprint in High-Margin Niche Fragrance Market
Feb 6, 2026 12:21 HKT/SGT
|
|
|
Distinct Healthcare Successfully Listed on HKEX, Bolstered by Premium Customer Base and All-Star Cornerstone Investors
Feb 6, 2026 11:44 HKT/SGT
|
|
|
Establishment of the World's First*1 Global Supply Chain to Introduce the Use of Renewable Plastics in Sony's High-Performance Products
Friday, February 6, 2026 10:50:00 AM
|
|
|
|
|
More Press release >> |
|
|
|
